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Abstract 
Background and Purpose 
Centres wishing to participate in international multicentre randomised controlled surgical 
trials such as STICH II (Surgical Trial in Lobar Intracerebral Haemorrhage) have to go 
through a number of regulatory hurdles. These depend on the nature of the study. In surgical 
studies there is a need to obtain ethical approval and individual hospital approval including 
fully executing contracts between the host organisation and each institution. Firsthand 
experience has been gained in STICH II by guiding over eighty hospitals through this 
process in over twenty different countries worldwide.  
Methods 
This paper examines the administrative challenges of setting up the STICH II trial which 
include the time that it has taken for each hospital to obtain ethical approval, sign the study 
agreement and become a fully registered site. The aim of this paper is to inform potential 
triallists planning multinational surgical trials about the potential delays and difficulties that 
may be encountered in the hope that it will encourage the medical research community to 
simplify administrative systems. We also hope to influence trial funders to build in ‘start up 
periods’ for new studies so that they can get up and running in a realistic time frame. The 
difficulties which were faced will be highlighted so that the organisers of other randomised 
controlled surgical trials can be aware of these delays.  
Conclusion 
From the experiences in this trial, it can be concluded that delays will be experienced in 
obtaining ethical approval and in agreeing on site contracts.
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Obtaining Regulatory Approval for Multicentre Randomised Controlled Trials: 
Experiences in the STICH II trial. 
 
 
Background 
 
Randomised controlled trials are designed to establish whether various treatments are 
clinically efficacious. The sample size for a trial is chosen to provide sufficient power to test 
the hypothesis. Usually the size of the sample is such that it is not possible to recruit all the 
patients from one centre within a realistic time period. It is therefore necessary to undertake 
a multicentre randomised controlled trial in these circumstances. If possible, such trials are 
often restricted to one country. The advantages of this include funding, unified regulatory 
issues, good communication between hospitals, ease of site visits, no translating errors and 
no language barriers or time differences. However, sometimes it can still take too long to 
recruit sufficient patients, and there is also a danger that the outcome of the trial can be 
considered biased to patients in one geographical region. It is sometimes therefore 
necessary to undertake an international multicentre study.  
Centres wishing to participate in international multicentre randomised controlled surgical 
trials such as STICH II (Surgical Trial in Lobar Intracerebral Haemorrhage) have to go 
through a number of regulatory hurdles. These depend on the nature of the study. In drug 
studies they will include obtaining competent authority or equivalent approval in each 
country. Even in surgical studies there is a need to obtain ethical approval and individual 
hospital approval including fully executing contracts between the host organisation and each 
institution. Firsthand experience has been gained in STICH II by guiding over eighty 
hospitals through this process in over twenty different countries worldwide. STICH II is an 
ongoing international multicentre randomised parallel group trial comparing early craniotomy 
to evacuate the haematoma with initial conservative treatment. Patients for whom the 
treating neurosurgeon is in equipoise about the benefits of early craniotomy are eligible for 
the trial. The objectives of the STICH II study are to establish whether a policy of earlier 
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surgical evacuation of haematomas in selected patients with spontaneous lobar ICH will 
improve outcome compared to a policy of initial conservative treatment.1 The trial will also 
help to better define the indications for early surgery. This will overcome two of the criticisms 
of the original STICH trial which were: timing was too late and sometimes location was too 
deep.2  
This paper examines the administrative challenges of setting up the STICH II trial which 
include the time that it has taken for each hospital to obtain ethical approval, sign the study 
agreement and become a fully registered site. The aim of this paper is to inform potential 
triallists planning multinational surgical trials about the potential delays and difficulties that 
may be encountered in the hope that it will encourage the medical research community to 
simplify administrative systems. We also hope to influence trial funders to build in ‘start up 
periods’ for new studies so that they can get up and running in a realistic time frame. The 
difficulties which were faced will be highlighted so that the organisers of other randomised 
controlled surgical trials can be aware of these delays.  
Results 
Table 1 below contains a list of countries and how many centres we have participating in 
STICH II in each of those countries. The complete registration process for STICH II, 
including completing an application form, obtaining ethical approval, agreeing on the contract 
and the site becoming registered has been split into separate parts. The first part measured 
was the time it took from receiving the application form to a centre obtaining ethical approval. 
Also measured was the time from obtaining ethical approval to signing and returning the 
STICH II site agreement. This then allowed an average for each country to be ascertained 
(shown in Figure 1). Also available in table1 are the minimum and maximum number of days 
that it took a country to complete the entire registration process for the STICH II study. 
Please note that it states zero days for Pakistan for obtaining ethics. This is because their 
application form and ethical approval arrived on the same day. 
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Country 
Number of Sites 
 
 
Average number of days from receiving 
application form to obtaining ethics 
 
 
Average number of days from receiving ethics 
to becoming registered 
Average number of days for centre to 
complete full registration process 
 
 
Minimum  number of days for country to 
complete full registration process 
 
 
Maximum number of days for country to 
complete full registration process 
Armenia 1 
58 57 
115 
115 115 
Australia 1 
148 229 
377 
377 377 
Austria 1 
172 110 
282 
282 282 
Canada 1 
383 9 
392 
392 392 
China 1 
120 36 
156 
156 156 
Czech Republic 4 
85 126 
210 
142 361 
Egypt 1 
60 149 
209 
209 209 
Georgia 1 
62 161 
223 
223 223 
Germany 17 
175 153 
320 
67 1504 
Greece 3 
131 53 
183 
31 237 
Hungary 2 
77 137 
214 
140 287 
India 8 
97 86 
184 
44 325 
Israel 1 
98 123 
221 
221 221 
Italy 1 
131 26 
157 
157 157 
Latvia 2 
58 53 
111 
51 170 
Lithuania 1 
48 21 
69 
69 69 
Macedonia 1 
103 93 
196 
196 196 
Mexico 2 
214 59 
273 
267 278 
Nepal 1 
54 49 
103 
103 103 
Norway 1 
161 158 
319 
319 319 
Pakistan 1 
0 58 
58 
58 58 
Poland 2 
99 117 
216 
116 315 
Romania 1 
53 56 
109 
109 109 
Russia 1 
40 91 
131 
131 131 
Saudi Arabia 1 
260 95 
355 
355 355 
Spain 4 127 163 290 172 535 
The Netherlands 1 
475 185 
660 
660 660 
Turkey 1 
85 85 
170 
170 170 
UK 16 
197 150 
347 
79 884 
USA 9 
194 147 
341 
111 513 
Table 1 
Break down 
of 
registration 
process. 
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Figure 1 
Graph comparing time to obtain ethical approval and 
time to complete contract signing. 
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Discussion 
Obtaining Ethics Approval 
As can be seen from table 1, there is a wide variation between countries in the time taken to 
obtain ethical approval. These differences have occurred for a variety of reasons. It is 
important to note that STICH II is not a pharmaceutical study. No devices are used and the 
two treatments under test are already practiced routinely. The protocol describes the 
randomisation process and the data collection requirements. The only additional procedure 
required is one extra CT done at 5 days and this is standard practice in most hospitals 
anyway. Many centres have misunderstood these aspects of the trial design and therefore 
ethical approval has taken longer to obtain whilst explaining this issue.  
The process of obtaining ethical approval is not standardised between countries or even 
within a country; this also causes great variation in the time it takes for hospitals to obtain 
approval. This is despite the ‘Harmonisation’ process agreed in Helsinki.3 Also, the 
frequency of ethical committee meetings can cause serious delays in approval being 
granted; some committees meet monthly, some quarterly and others only twice a year.4  
As well as ethical committees not meeting very often, in some countries they charge a fee 
for undertaking the review. Some sites in STICH II have asked us to pay this charge for 
them, however, our funding does not provide for such costs. The STICH Team has therefore 
had to stipulate that in countries where this is a requirement, the local investigators cover the 
payment initially and then recover the cost from the per patient payments once they start to 
recruit patients; this may therefore have deterred some hospitals from taking part.  
If a consultant is new to research, the time it takes to obtain ethical approval is undoubtedly 
longer. This is because they are not familiar with the complex process and so require a lot of 
assistance.  
In the UK, the process is slow, the average number of days taken to obtain ethical approval 
is 197. Most of the UK sites participating in STICH II went through on the old COREC 
system where they needed to obtain separate Ethical Committee approval and Research 
and Development approval at each site.5 This added a lot of time onto the process. It is 
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hoped that the new National Institute for Health Research Coordinated System for Gaining 
NHS Permission (CSP) system may speed up the process of local approval for UK sites in 
the future. 
The nature of this study in acutely ill patients is such that the majority of patients are unable 
to provide consent themselves. The interpretation of recent changes in legislature in some 
countries with regards to whether consent/assent can be provided by someone else has 
caused many problems in getting ethical approval, particularly in Lithuanian centres. In some 
centres, if a patient is unable to consent themselves into the trial then they are not allowed to 
participate. This has caused problems with recruitment; we have tried to solve this by 
holding a meeting in Lithuania and inviting members of the government and members of 
ethical committees, to discuss this issue. Our hope is that there will be a reassessment with 
regards to unconscious patients which will allow their relatives to provide consent for them to 
enter into the trial or some other procedure will be put in place so that research can be 
undertaken on these patients. Nevertheless, some countries, in their interpretations of the 
regulations, just do not allow for these patients to be included in surgical trials whatever 
happens.  
Despite many problems working against obtaining ethical approval, it is good to know that if 
two or more hospitals in the same city wish to participate, they can generally use the same 
ethical approval where the committee is the same. This greatly increases the speed at which 
the second and subsequent hospital can obtain approval. They must still inform the ethical 
committee but the process is greatly speeded up.  
Tripartite Agreements/Contracts 
STICH II is an academic study at Newcastle University (i.e. not commercially sponsored) 
and therefore requires sponsorship from the local NHS Trust (Newcastle upon Tyne 
Hospitals NHS Foundation Trust). A tripartite contract was therefore required to be drawn up 
between the University, NHS Trust and the prospective participating centres. Once each 
hospital obtains ethical approval the contract therefore needs to be personalised and signed. 
Many problems have however been experienced during this process.  
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Issues about Intellectual property arise many times. Essentially, ‘Intellectual Property’ is the 
phrase that describes the rights of the STICH II trial team to protect any results that are 
collected.6 Some centres from academic backgrounds however have also wanted to protect 
their own intellectual property. This means that they often want to insert into the STICH II 
agreement complicated paragraphs that would allow them to publish their personal results. 
This however is a problem because it could lead to the integrity of the trial being threatened 
if any centre published their results prior to the full study results being published. This can be 
resolved by indicating that the initial paper will be a joint publication but allowing a site to 
publish their own results after this or at a set time after failure to publish the joint results. 
Attempting to estimate the length of time that it would take to obtain publication of the final 
complete trial results is problematic because of the number of unknowns, e.g. how many 
journals will need to review the paper before it is accepted, how long will the reviewer take 
and then once the paper is accepted how long to publication.  
The issue of insurance has also been raised many times when trying to finalise the contract 
for some hospitals. This main concern is about insurance to cover design of the trial and also 
the difference between medical care and research.  
With regards to medical negligence, it has been agreed that there can be no breach in the 
duty of care of a patient so long as the doctor acted in accordance with a responsible body 
of medical opinion. This is known as the ‘Bolam test’, which is a test used to determine the 
standard of care owed to a patient by doctors.7 Patients who are included in the STICH II 
trial receive the same level of care as someone who refused to enter the trial.8 Thus, there is 
no difference between the standard of medical care in or out of the clinical trial. These 
insurance issues have occurred, particularly with American and Israeli sites. Many hospitals 
in these countries have sadly not been able to take part because their legal advisors expect 
the co-ordinating site (in this case, Newcastle), to provide adequate insurance for their 
patients. All we ask is that the participating hospital has adequate insurance in place as a 
routine to cover their doctors for the normal care of these patients. This problem is also often 
10 
experienced if the hospital has misunderstood the nature of the trial and believes it to be a 
pharmaceutical trial.  
The design of the STICH II trial is also indemnified by the Newcastle upon Tyne NHS 
Foundation Trust. This ensures that a patient cannot claim against the investigators for 
design of the trial itself. However, in a study such as STICH II this is extremely unlikely as it 
is an MRC funded study and is simply comparing two already widely practiced methods of 
treatment. Furthermore, if there is a dispute with this issue, it clearly states in the STICH II 
contract that English Law applies. Some centres have had a problem with this. It is usually 
solved by agreeing to remain silent on the issue.  
When negotiating clauses in the contract we always aim to maintain an equitable approach. 
The original contracts drawn up in 2006 stated that the only laws that applied were the laws 
of England and Wales.  We came to the compromise we now have whereby any claims 
against another institution have to be made according to the law of their country but any 
claims against our university/hospital have to be made according to our laws. This was felt 
be a fair and even-handed approach to a UK funded study.  Also given the nature of the 
organisation employing those who designed the study, where there is no study drug and 
where the treating clinician remains responsible for the treatment of the patient at all times, 
this situation is highly unlikely to arise. 
Around twenty hospitals which were progressing through the registration process have 
unfortunately had to stop participating. This is because the agreements could not be settled. 
Ethical approval may have already been obtained but if the legal departments could not 
agree on the wording of the contract, progression unfortunately stopped. So, although the 
clinicians are in agreement, the administrators are not. 
Issues about the destinations of per patient payments have also delayed the contract 
agreement process. For the STICH II trial it is essential that the per patient payments for this 
MRC funded trial are not paid to individuals. If a research account is not available, as in a 
number of cases, one therefore needs to be opened. This is because money from a public 
source such as the MRC cannot be transferred into a personal account; it is solely for 
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research and the only way to ensure that this money is used for the correct purposes is to 
ensure a research account is being used.  
We have tried to improve the time it takes to resolve contractual issues in STICH II. We 
requested that our institution assign a properly trained and qualified member of staff to assist 
us. Medical research staff are not qualified to resolve legal matters and therefore this 
seemed a sensible course of action. We have also appointed lead people in each country 
with centres for STICH II. This is because if hospitals experience any difficulties they have a 
point of call to go to locally. This helps to speed up the process as documents have already 
been translated and communication can be easy and with no language barriers. 
Conclusion 
From the data table and graph shown earlier it is possible to conclude that only 40% of sites 
obtained ethical approval more quickly than they had agreed on the contract. This seems to 
indicate that there are many barriers which must be resolved with ethical committees. These 
delays are severely disabling research. This conclusion comes six years after all EU 
member states implemented the Clinical Trials Directive. This highlights that it has not been 
a complete success. The Clinical Trials Directive was introduced to try and create a 
harmonised framework for clinical research and improve ethical reviews. However, all EU 
countries that have adopted this, have interpreted it in different ways.9 This has led to 
fragmentation and division. Essentially this is making it harder to include patients into 
research. In the STICH II trial, it could take up to 400 days to obtain ethical approval. The 
extraordinary length of time that it is taking to pass through the ethical committee process is 
shortening the time remaining available to carry out the research. 
From the experiences in this trial, it can be concluded that delays will be experienced in 
obtaining ethical approval and in agreeing on site contracts. This problem has been 
recognised in a recent article in the British Medical Journal.10 These delays are occurring 
even after following the developed and revised CONSORT (CONsolidated Standards of 
Reporting Trials) Statement. This was designed to help authors improve reporting of two-
parallel design RCTs by using a checklist and flow diagram.11 Health care organisations and 
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universities need to give much more support to researchers so that more time can be spent 
on the research and less time spent on the bureaucratic affairs. 
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